- Open Access
Porous deproteinized bovine bone scaffold with three-dimensional localized drug delivery system using chitosan microspheres
© Li et al.; licensee BioMed Central. 2015
- Received: 16 October 2014
- Accepted: 30 March 2015
- Published: 15 April 2015
Bone substation grafts, such as hydroxyapatite (HA) and tricalciumphosphate (TCP), have been extensively used in clinical applications, but evidence suggests that they offer poor osteoinductive properties compared to allografts and autografts. In order to increase bone growth with such grafts, Bone Morphogenetic Protein 2 (BMP-2) was incorporated into a three dimensional reservoir. The purpose of the present study was to develop a novel drug delivery system which is capable of controlled release of BMP-2.
DBB were prepared from bovine cancellous bone harvested from fetal bovine femur or tibia and then sinting at 1000°C. BMP-2-loaded chitosan (CS) microspheres were fabricated by cross-linking. Then the treated DBB powders were blended with chitosan microspheres solution. Finally, the composites were lyophilized with a freeze dryer to obtain the DBB/CMs scaffolds. X-ray diffractor (XRD), scanning electron microscopy (SEM) and Fourier transform infrared (FT-IR) were used to characterize the sample. The quantification of the delivery profile of BMP-2 was determined using an enzyme-linked immunosorbent assay (ELISA) kit. The in vitro assays were to characterize the biocompatibility of this composite.
In this study, BMP-2/Chitosan (CS) microspheres were successively loaded onto a deproteinized bovine bone (DBB) scaffold. The release profile of BMP-2 indicated an initial burst release followed by a more even sustained release. An in vitro bioactivity assay revealed that the encapsulated growth factor was biologically active.
The cell culture assay suggest that the excellent biocompatibility of the DBB- BMP-2/CS. Therefore, this novel microsphere scaffold system can be effectively used in current tissue engineering applications.
- Deproteinized bovine bone (DBB)
- Drug delivery system
An increasing number of patients suffer from bone defects that require transplantation . However, bone grafting, the gold standard in bone defect management, bears considerable risks; donor site pain and morbidity, infection, increased blood loss, and longer operating times [2-4]. The most common alternative is to use human cadaveric bone (allograft), which has additional disadvantages, including rejection, limited supply, and potential disease transmission. Interest has thus focused on animal bone (xenograft) that exhibits physiological and chemical properties similar to autologous bone. But inherent complications with immunogenicity and disease transmission also hinder the effectiveness of this method .
For an ideal bone tissue engineering scaffold, one of the most important criteria is that the scaffold consists of a highly interconnected porous network with pore sizes large enough for cell migration, fluid exchange, and eventually tissue ingrowth and vascularization. Although synthetic calcium phosphate ceramics (such as β-tricalciumphosphate (β-TCP) , and hydroxyapatite (HA) ) with their excellent biocompatibility are designed to mimic the native extracellular matrix as closely as possible , the porous network of the artificial bone scaffold still cannot compare to natural bone in terms of structure and function.
There is a growing need to provide alternatives to traditional bone grafting. Deproteinized bovine bone (DBB)  manufactured from natural materials, such as coral or natural bone, has the advantage of inheriting the properties of the raw source materials, including the pore structure. Because all organic material is removed by stepwise annealing (up to 300°C), there is no need for concern with immunogenicity or disease transmission. Therefore, this kind of inorganic porous bone has gained wide acceptance for various dental and medical applications; e.g. fillers for periodontal defects, alveolar ridge augmentation, maxillofacial reconstruction, dental implants and spine fusion. DBB has been widely used in dentistry as an alternative to autologous bone grafts. Although DBB provides an osteoconductive scaffold, it is not capable of enhancing bone regeneration because it is not osteoinductive.
In addition, during the bone healing process, the constant remodeling activities are coordinated and controlled by various growth factors, such as TGF-β, PDGF, FGF-2, and BMPs . The osteoinductive capacity of bone morphogenetic proteins (BMPs), especially BMP-2, have been proven to promote osteogenic differentiation . BMP-2 is now approved by the U.S. Food and Drug Administration (FDA) for restricted clinical use in open tibial fractures and anterior spinal fusion. In order to render DBB osteoinductive, bone morphogenetic protein 2 (BMP-2) has previously been incorporated into a three dimensional reservoir (a biomimetic calcium phosphate coating) on DBB, which effectively promoted the osteogenic response by the slow delivery of BMP-2. Despite the proven efficacy of BMP, its clinical application is complicated by its short biological half-life, systemic side effects and rapid clearance . Delivery systems that minimize BMP diffusion away from its therapeutic target are desirable not only for enhancing bone formation, but also for limiting unwanted pathologies.
In order to retain the BMPs at the site for a prolonged period of time , delivery via microspheres synthesized by chitosan may be used. Chitosan has been widely used for the controlled delivery of peptides or proteins in the form of microspheres, due to its excellent biological properties such as biodegradability, biocompatibility, non-toxicity, bacteriostaticity and strong adhesion . The chitosan used for the synthesis of these microspheres can be both degradable  as well as non-degradable . Incorporation of the molecules in these microspheres allows controlled diffusion and exposes the protein molecule for a longer duration.
In this study, deproteinized bovine bone (DBB) and chitosan were chosen as carriers for BMP-2 delivery to overcome the disadvantage of rapid clearance typically associated with BMP-2. Firstly, chitosan microspheres (CMs) loaded with BMP-2 were prepared by an emulsion-ionic cross-linking method. Secondly, CMs with BMP-2 was embedded into DBB by a dip-coating process using the capillarity of the material. The purpose of this study was to increase the efficiency of this microsphere-scaffold as a carrier for growth factors and to estimate the osteogenic effect of this microsphere-scaffold as a potential candidate for bone tissue engineering.
Preparation of the DBB scaffold
Samples were prepared from bovine cancellous bone harvested from fetal bovine femur or tibia. Using a diamond saw, the cancellous bones were sectioned into 3 mm × 3 mm × 40 mm blocks. The fatty bone marrow was removed by immersion in 30% H2O2 for 2 h. The bone was washed with water and immersed in 1% H3PO4 for heating in a water bath at 125°C for 2 h. The bone was washed with 95% alcohol to remove any residual moisture that could cause small cracks during heat treatment. Following air drying for at least 12 h, the bone underwent heat treatment in a furnace (Siliconit muffle furnace, Kwangsung Science Co., Korea) with a heating rate of 10°C/min up to 1000°C. This temperature was maintained steady for 2 h under 1 atm of pressure. To obtain constant size particles of 0.25-1 mm and 1-2 mm, a sieve with corresponding mesh size was used. After ultrasonic cleaning and drying, the deproteinized bovine bones were obtained.
Preparation of BMP-2 loaded chitosan microspheres
BMP-2-loaded chitosan (CS) microspheres were fabricated by cross-linking. Briefly, CS polymer with a viscosity of 150–900 cP and 75–85% deacetylation was purchased from Sigma-Aldrich (Shanghai, China), and then refined twice by dissolving in aqueous acetic acid solution and precipitating from dilute ammonia. The BMP-2 was also obtained from Sigma-Aldrich. A CS solution (10 g/l) was prepared by dissolving CS in 2.3% (v/v) aqueous acetic acid solution. 500 mg of this CS solution and the different contents of BMP-2 (0.75 μg/ml, 1 μg/ml, 1.25 μg/ml) were mixed and then the cross-liker was added (vanillin 1% v/v ethanol aqueous solution). The emulsified solution was immediately poured into the CS-BMP-2 mixture and stirred with a magnetic stirrer for 4 h so as to allow the solvent to evaporate. The hardened microspheres were then collected by centrifugation at 3000 rpm for 3 min, washed three times with distilled water, and lyophilized using a freeze dryer.
Preparation of DBB/CMs scaffold
Preparation of BMP-2-loaded CS microspheres on DBB scaffold surfaces was performed in the following process. In the first-step, DBB powders were radiofrequency (RF) plasma glow-discharged (PDC-32 G, Harrick Plasma, USA) in an oxygen-filled chamber at a pressure of 200 mTorr Pa. The plasma power density and the treatment time were fixed at 30 W and 120 s, respectively. Then the treated DBB powders were blended with different contents of chitosan microspheres solution and poured into a polystyrene mold, and frozen at −20°C overnight. Finally, the composites were lyophilized with a freeze dryer to obtain the DBB/CMs scaffolds.
Characterization of materials
XRD was used to determine the structure of the synthesized DBB. XRD measurements were performed with an X-ray diffractor [D/max-II; X-ray Diffractometer (XRD), RIGAKU, Japan] (Cu-Ka). The samples were measured in the 2θ range from 10° to 70° (scan speed of 0.02° per second).
The morphology of the obtained chitosan microspheres and DBB scaffolds was examined by a scanning electron microscopy (SEM, S-2400; Hitachi, Japan).
Chemical analysis of the DBB, CS and DBB/CMs materials was carried out by a Fourier transform infrared (FT-IR) spectrophotometer (FTIR 650) in the range from 4000 cm−1 to 400 cm−1 at a resolution of 3 cm−1, averaging 100 scans.
In vitro release profile
The quantification of the delivery profile of BMP-2 (0.75 μg/ml, 1 μg/ml, 1.25 μg/ml) from this system was determined using an enzyme-linked immunosorbent assay (ELISA) kit (PeproTech EC, London, UK) .
In vitro study
Mouse calvaria-derived, pre-osteoblastic cells MC3T3-E1 were cultured as monolayers in Alpha Minimum Essential Medium (α-MEM, GIBCO), supplemented with 10% (v/v) fetal bovine serum (FBS; Sigma), 1% (v/v) L-glutamine (Invitrogen Corp., Carlsbad, CA, USA), and a 1% (v/v) antibiotic and antimycotic formulation (containing penicillin G sodium, streptomycin sulfate (Invitrogen Corp., Carlsbad, CA, USA). The medium was changed on alternate days, and the cultures were maintained at 37°C within a humidified atmosphere containing 5% CO2.
When the confluence reached 90%, the cells were passaged (P1). After passaging three times (P3), the cells were exposed to proliferation assays using CCK8 kits at 3d, 5d, 7d, 14d to study the impact of BMP-2 on the multiplication of MC3T3 cells. The cells were assigned into BMP-2 groups (0.75 μg/ml, 1 μg/ml, 1.25 μg/ml) and a control group.
Each cell suspension (5 ml) was plated at a density of 1 × 106 cells ml−1 in plates containing sterile samples of microsphere-scaffolds for the cell attachment assays. SEM micrographs were taken at 1 day following the initial cell co-culturing with the scaffolds. Briefly, the co-cultured constructs were harvested, washed with PBS and then fixed with 4% glutaraldehyde. Following 3 rinses with water, these samples were dehydrated through a series of graded alcohol solutions and then air-dried overnight. The samples were observed by SEM at an accelerating voltage of 30 kV (QUANTA 250 FEG, USA).
Differentiation of cells on microsphere-scaffold
MC3T3-E1 cells were seeded with new medium. When the density reached 10% after 3 passages, about 1 × 106 cells were seeded on T25 flasks. Then these colonies were switched to an osteo-inducing medium (a-MEM, 10-8 M dexamethasone, 50 μg/ml ascorbic acid, 10 mM ß-glycerophosphoric acid). The cells were assigned into a BMP-2 group and control group respectively. Samples from each group were collected at 3d and 7d for western blotting and real-time PCR analysis.
MC-3 T3 cells were lysed in an RIPA buffer supplemented with protease inhibitors (#11-10601, SinoGene Scientific, Beijing China) and phosphatase inhibitors (#11-10701, SinoGene Scientific, Beijing China). Protein concentration was determined using the Bradford method. 30 μg protein lysate was mixed with 2× loading buffer at 1:1 and heated for 10 min at 95°C before being loaded for gel electrophoresis.
The proteins and protein marker (SM1881, Thermo Fermentas) were separated by SDS-PAGE (4% stacking gel, 12% separating gel) at 120 V for 2 h. Proteins were transferred to PVDF membranes using a Bio-rad mini transfer system. The membranes were blocked in rapid blocking Buffer (#66-11402, SinoGene) for 5 min and then probed with primary antibodies against ALP, BMP-2, OST and RUNX2 at a dilution of 1:1000 for 2 h. After washing 3 times with PBS, at 10 min per wash, HRP-conjugated anti rabbit and anti-mouse antibodies (10104, 10105, Miroanalysis Inc.) were applied to the membranes at a dilution of 1:2000 for 1 h. Chemiluminescent signals were developed using a ECL Kit (ECL, 29050, Engreen) and exposed to X-ray films in a dark room. Then the membranes were stripped by a stripping buffer (#66-11501, SinoGene Scientific) and reprobed with ß-actin (M20010, Ab-mart). The level of actin was measured as an internal control.
Real-time PCR analysis
Total RNA was isolated from samples using an SG TriEx HiPure RNA Extraction Kit (#55-11120, SinoGene Scientific, China). RNA concentration was measured at 260 nm and its purity was assessed with Biophotometer (Eppendorf, Germany) at a ratio of 260:280 nm. RNA samples were treated with DNaseI (EN0523, Fermentas) to remove contaminating genomic DNA and analyzed on 1.5% agarose gels. Reverse transcription was performed with a Thermo First cDNA Synthesis Kit (#33-20102, SinoGene Scientific China) with random hexamer primers. The average amount of RNA used in the reverse transcription reaction was 1 μg and its purity was around 2.0 (260:280 nm ratio).
Chain reaction primers used for detection in this study
Product size (bp)
All experiments involving the use of animals were incompliance with Provisions and General Recommendation of Chinese Experimental Animals Administration Legislation and were approved by Beijing Municipal Science & Technology Commission (Permit Number: SCXK (Beijing) 2006-0008and SYXK (Beijing) 2006-0025).
Data is given as means ± S.E.M. for statistical comparison, t-test or one-way ANOVA followed by Tukey’s test was used.*p < 0.05, **p < 0.01 and ***p < 0.001 were considered to be statistically significant.
SEM of CMs
In Figure 4b, the characteristic peaks of pure CS are displayed at 1655 cm−1, which can be assigned to the absorption of amide I carbonyl stretching, while the peak of carbonyl stretching shifted to 1643 cm−1 in Figure 4c. This change signifies interaction between CS and DBB.
Attachment and proliferation of cells on DBB/CMs/BMP-2 scaffold
Differentiation of cells on CMs- scaffold
Fold-change of different gene expressions after BMP-2 treatment
Day 7 CON
Day 7 Trt
1 ± 0.1716
4.637 ± 0.3565***
1.003 ± 0.4517
5.077 ± 0.08647***
1 ± 0.08
2.64 ± 0.13**
1 ± 0.2894
7.483 ± 1.058**
1.003 ± 0.2128
1.823 ± 0.3724*
1 ± 0.1856
25.94 ± 4.835**
0.9967 ± 0.1073
0.87 ± 0.1626
1 ± 0.2649
0.2404 ± 0.02242
Osteoblast cells were noted to proliferate on the materials on day 7 of culture; and the osteoblasts in the DBB/CMs scaffold without BMP-2 showed a lower increase on the 7th day of culture compared with those cultured on the other days. In contrast, cells growing on the DBB/CMs/BMP-2 scaffold did not show an increased tendency for proliferation at the same time point either with BMP-2. According to the data of the proliferation assay, the osteoblast cells in the DBB/CMs/BMP-2 scaffold had higher proliferation rates within 7 days than the controls, which indicated that the BMP-2 promoted cell proliferation. The osteoblast cells in this novel drug delivery system reached the end of first period faster than the control, which implied that the applied BMP-2 was beneficial to the osteoblast cells’ differentiation as well. Hence, Figure 9 not only shows the tendency for osteoblast proliferation induced by the drug delivery scaffold with or without BMP-2, but also indirectly reflects osteoblast differentiation.
The main objective of this study was to investigate BMP-2/CMs scaffolds as potential dual-drug/protein delivery systems for slow and sustained delivery of different bioactive agents. The retrieved data confirmed that a gradual, sustained, and cell-mediated release of bioactive agents can be achieved in vitro using a BMP-2/CMs scaffold. Moreover, the DBB/CMs scaffold loaded with BMP-2 showed excellent osteoinductivity.
In designing a matrix for differentiation factor release, it is apparent that the extremes of release (bolus injections or prolonged low level release) are not beneficial to bone induction. A further complicating factor is that different anatomical sites might require different kinetics of release for optimal performance. For example, in more fluid environments or compromised (avascular) sites, BMP clearance might be faster than the bone-induction response of the host. In these cases a slow-release system may be required. It has been suggested that bone repair therapy is influenced not just by the amount of protein present but also by the duration of protein production. So an important issue when accessing growth factors for local bone repair is to identify an ideal drug delivery carrier which can ensure a sufficient protein concentration and effect at the application site for the duration of the healing process, and therefore provide an appropriate support for bone repair. In the current study, the BMP-2 release resulted in a gradual, sustained protein release pattern. Further investigations are needed to analyze the in vivo release of BMP-2.
The degradability of CaP-based materials is very important for the in vivo longevity and efficacy of its biological effects. The findings of this study indicate that CMs scaffolds are degradable and both in vitro and in vivo results indicate that the coating can prevent and delay the degradation of underlying Bio-CaP, even though the coating is biodegradable.
The coating and Bio-CaP were all biomimetically formed by precipitation of calcium phosphate. However, their surface structures were totally different before coating. It was demonstrated that BMP-2 incorporated into biomimetic coatings can retain its biological activity and that the growth factors released through osteoclastic activity could significantly promote osteoblastogenesis in vitro. Therefore, we assume that BMP-2 maintains its activity. However, further investigations are needed to prove the specific activity of BMP-2.
In bone tissue engineering, osteoblast cells are one of the most crucial factors that lead to the ultimate formation of new bone tissue. The ECM proteins function as a substratum for bone cell adhesion and serve as a scaffold for mineralization . In the current work, the constructs of the CMs scaffold drug delivery system of DBB/CMs/BMP-2 were observed with SEM after culturing with an osteogenesis-inducing medium for 7 days (Figure 6). In general, cells growing on the DBB/CMs scaffold revealed many typical globular round cells which integrated with the scaffold. In particular, the DBB/CMs/BMP-2 group showed that the cells growing on this material were surrounded by a thick substance. The reason is that the BMP-2 produced many substances on the surface of the original scaffold, which assisted the osteoblasts growth. Besides, BMP-2 also assisted the proliferation tendency of the osteoblasts induced by the drug delivery scaffold (Figures 8 and 9).
Our findings strongly suggest that this CMs scaffold can be used as an effective protein delivery vehicle. In addition, the use of the coating can offer an alternative for slow release. CMs scaffolds can offer a dual-release system for a sequential delivery of different proteins/drugs. This combination could be applicable for a variety of clinical applications. For example, osteogenic agents can be incorporated into the interior of CMs scaffolds, and at the same time, antibiotics can be incorporated into the surface coating. This could be considered as a new strategy for the treatment of bone defects caused by peri-implantitis. In conclusion, it was shown that the CMs scaffold with an internal or surface-coated depot of protein has the capacity to maintain a slow and sustained protein release in the presence of osteoclasts in vitro. Further investigations are needed to prove the in vivo release and actual activity of BMP-2. The dual-drug release system offers a promising tool for the controlled delivery of multiple therapeutic agents, such as antibiotics, osteogenic agents, and anti-cancer drugs for different clinical applications.
A functional scaffold loading microspheres system was successfully developed and shown to be an excellent drug delivery platform for bone regeneration. BMP-2 as a model bioactive molecule was efficiently added to the microsphere-loading DBB scaffold with perfect biocompatibility, and offered efficient release kinetics of BMP-2. Therefore, this novel CS microsphere-loaded DBB scaffold system may be applicable as a promising scaffold for bone regeneration.
This study was supported by funds from Capital Public Health Project (z2110005312001), NSFC Research Grant (11002016, 11120101001,10925208, 61227902), National Basic Research Program of China (973 program, 2011CB710901), National Key Technology R&D Program (No. 2012BAI18B06, 2012BAI18B05), the 111 Project of China (No. B13003), International Joint Research Center of Aerospace Biotechnology.
- Shang F, Ming L, Zhou Z, Yu Y, Sun J, Ding Y, et al. The effect of licochalcone A on cell-aggregates ECM secretion and osteogenic differentiation during bone formation in metaphyseal defects in ovariectomized rats. Biomaterials. 2014;35:2789–97.View ArticleGoogle Scholar
- Thormann U, Ray S, Sommer U, Elkhassawna T, Rehling T, Hundgeburth M, et al. Bone formation induced by strontium modified calcium phosphate cement in critical-size metaphyseal fracture defects in ovariectomized rats. Biomaterials. 2013;34:8589–98.View ArticleGoogle Scholar
- Meyer Jr RA, Tsahakis PJ, Martin DF, Banks DM, Harrow ME, Kiebzak GM. Age and ovariectomy impair both the normalization of mechanical properties and the accretion of mineral by the fracture callus in rats. J Orthop Res. 2001;19:428–35.View ArticleGoogle Scholar
- Namkung-Matthai H, Appleyard R, Jansen J, Hao Lin J, Maastricht S, Swain M, et al. Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. Bone. 2001;28:80–6.View ArticleGoogle Scholar
- Fairbairn NG, Randolph MA, Redmond RW. The clinical applications of human amnion in plastic surgery. J Plast Reconstr Aesthet Surg. 2014;67:662–75.View ArticleGoogle Scholar
- Chen Z, Wu C, Gu W, Klein T, Crawford R, Xiao Y. Osteogenic differentiation of bone marrow MSCs by beta-tricalcium phosphate stimulating macrophages via BMP2 signalling pathway. Biomaterials. 2014;35:1507–18.View ArticleGoogle Scholar
- Muller KH, Motskin M, Philpott AJ, Routh AF, Shanahan CM, Duer MJ, et al. The effect of particle agglomeration on the formation of a surface-connected compartment induced by hydroxyapatite nanoparticles in human monocyte-derived macrophages. Biomaterials. 2014;35:1074–88.View ArticleGoogle Scholar
- Van Manen EH, Zhang W, Walboomers XF, Vazquez B, Yang F, Ji W, et al. The influence of electrospun fibre scaffold orientation and nano-hydroxyapatite content on the development of tooth bud stem cells in vitro. Odontology. 2014;102:14–21.View ArticleGoogle Scholar
- Wiltfang J, Jatschmann N, Hedderich J, Neukam FW, Schlegel KA, Gierloff M. Effect of deproteinized bovine bone matrix coverage on the resorption of iliac cortico-spongeous bone grafts - a prospective study of two cohorts. Clin Oral Implants Res. 2014;25:e127–32.View ArticleGoogle Scholar
- Garcia EV, Valdecantos PA, Barrera D, Roldan-Olarte M, Miceli DC. Bone morphogenetic proteins in the bovine oviduct: differential expression of BMP-5 in the isthmus during the estrous cycle. Theriogenology. 2014;81:1032–41.View ArticleGoogle Scholar
- Rahman CV, Ben-David D, Dhillon A, Kuhn G, Gould TW, Muller R, et al. Controlled release of BMP-2 from a sintered polymer scaffold enhances bone repair in a mouse calvarial defect model. J Tissue Eng Regen Med. 2014;8:59–66.View ArticleGoogle Scholar
- Imamura K, Maeda S, Kawamura I, Matsuyama K, Shinohara N, Yahiro Y, et al. Human immunodeficiency virus type 1 enhancer-binding protein 3 is essential for the expression of asparagine-linked glycosylation 2 in the regulation of osteoblast and chondrocyte differentiation. J Biol Chem. 2014;289:9865–79.View ArticleGoogle Scholar
- Almodovar J, Guillot R, Monge C, Vollaire J, Selimovic S, Coll JL, et al. Spatial patterning of BMP-2 and BMP-7 on biopolymeric films and the guidance of muscle cell fate. Biomaterials. 2014;35:3975–85.View ArticleGoogle Scholar
- Allouche FN, Guibal EE, Mameri N. Preparation of a new chitosan-based materials and its application for mercury sorption. Colloids Surf A Physicochem Eng Asp. 2014;446:224–32.View ArticleGoogle Scholar
- Abdelgawad AM, Hudson SM, Rojas OJ. Antimicrobial wound dressing nanofiber mats from multicomponent (chitosan/silver-NPs/polyvinyl alcohol) systems. Carbohydr Polym. 2014;100:166–78.View ArticleGoogle Scholar
- Ferrand A, Eap S, Richert L, Lemoine S, Kalaskar D, Demoustier-Champagne S, et al. Osteogenetic properties of electrospun nanofibrous PCL scaffolds equipped with chitosan-based nanoreservoirs of growth factors. Macromol Biosci. 2014;14:45–55.View ArticleGoogle Scholar
- Liu Y, De Groot K, Hunziker EB. BMP-2 liberated from biomimetic implant coatings induces and sustains direct ossification in an ectopic rat model. Bone. 2005;36:745–57.View ArticleGoogle Scholar
- Meng J, Zhang Y, Qi X, Kong H, Wang C, Xu Z, et al. Paramagnetic nanofibrous composite films enhance the osteogenic responses of pre-osteoblast cells. Nanoscale. 2010;2:2565–9.View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.